Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UM171-Expanded Cord Blood Transplantation in High-Risk Acute Leukemia/Myelodysplasia
2024-517583-36-01Phase 2Authorised
- Sponsor
- ExCellThera
- Start
- Nov 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dorocubicel in leukemia and myelodysplastic syndrome (MDS), sponsored by ExCellThera. Primary endpoints: Relapse-free survival at 1 year post-transplant and Relapse-free survival at 2 years post-transplant. Planned start Nov 2024; status: authorised.
02
Drugs
dorocubicel
03
Conditions
leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-517583-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517583-36-01.